Hydrogen Gas Therapy in Schizophrenia: Potential Neuroprotective Effects From an Animal Study.
Nobumi Miyake, Toshiaki Haga, Shin-Ichi Hirano, Yusuke Ichikawa, Yoshiyo Oguchi, Kumiko Ando · Neuropsychopharmacology reports · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
Neutral Summary
In male C57BL/6 mice, mK-801 administration significantly reduced HORAC levels, whereas hydrogen gas therapy markedly restored them. These preclinical findings add evidence about the molecular-hydrogen effects, outcomes, and biological pathways measured in this model.
Hydrogen Intervention
Other or not reported
Additional Notes
H2HUBB TAKEAWAY
In male C57BL/6 mice, mK-801 administration significantly reduced HORAC levels, whereas hydrogen gas therapy markedly restored them. These preclinical findings add evidence about the molecular-hydrogen effects, outcomes, and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in male C57BL/6 mice. MK-801 administration significantly reduced HORAC levels, whereas hydrogen gas therapy markedly restored them.
What the Researchers Studied
The researchers studied male C57BL/6 mice. The study used a preclinical animal experiment.
What Effects Did Molecular Hydrogen Have?
Reported treatment duration: 4 weeks. MK-801 administration significantly reduced HORAC levels, whereas hydrogen gas therapy markedly restored them. The authors concluded that hydrogen gas therapy does not significantly ameliorate behavioral abnormalities in the MK-801-induced schizophrenia-like mouse model but exerts beneficial antioxidant effects. This study investigated whether inhalation therapy with hydrogen gas, a selective antioxidant, could reduce oxidative stress and improve behavioral outcomes in an MK-801-induced schizophrenia-like mouse model.
Why These Findings Matter
This publication adds useful evidence about where molecular hydrogen did and did not change the measured outcomes, helping define the larger therapeutic evidence base.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was male C57BL/6 mice. The study used a preclinical animal experiment. The reported treatment duration was 4 weeks.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.